EP Patent

EP3702456A1 — Crispr having or associated with destabilization domains

Assigned to Massachusetts Institute of Technology · Expires 2020-09-02 · 6y expired

What this patent protects

The disclosure includes non-naturally occurring or engineered CRISPR Cas9, each associated with at least one destabilization domain (DD), along with compositions, systems and complexes involving the DD-CRISPR Cas9, nucleic acid molecules and vectors encoding the same, delivery sy…

USPTO Abstract

The disclosure includes non-naturally occurring or engineered CRISPR Cas9, each associated with at least one destabilization domain (DD), along with compositions, systems and complexes involving the DD-CRISPR Cas9, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses therefor.

Drugs covered by this patent

Patent Metadata

Patent number
EP3702456A1
Jurisdiction
EP
Classification
—
Expires
2020-09-02
Drug substance claim
No
Drug product claim
No
Assignee
Massachusetts Institute of Technology
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.